2007•The Journal of Clinical PsychiatryRequires access

A study of aripiprazole and risperidone in treatment of schizophrenia

Qin Huang

Abstract

Objective:To observe the adverse events and efficacy of aripiprazole in the treatment of schizophrenia.Method:Sixty-four cases of schizophrenia were randomly divided into aripiprazole group and risperidone group.The course of treatments was 8 weeks.The therapeutic effects were evaluated by positive and negative symptom scale(PANSS),and side effects were assessed by treatment emergent symptom scale(TESS).Results:The rates of marked improvement in aripiprazole group and risperidone group were 78.1% and 75.0% respectively.The extracorticospinal(EPS) tract reaction was more severe in risperidone group than in aripiprazole group.Conclusion:Aripiprazole,as well as risperidone,is one of effective antipsychotics and less EPS in the treatment of schizophrenia.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Aripiprazole, Risperidone, Schizophrenia (object-oriented programming), Negative symptom, Positive and Negative Syndrome Scale, Psychology, Adverse effect, Medicine